Skip to main content

Evrysdi News

FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

SOUTH PLAINFIELD, N.J., May 31, 2022 /PRNewswire/ – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi...

FDA Approves Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older

South San Francisco, CA – August 7, 2020 – Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi (risdiplam) for treatment of...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Spinal Muscular Atrophy

Evrysdi patient information at Drugs.com